title: The NPM1 mutation type has no impact on survival in cytogenetically normal AML.
abstract: NPM1 mutations represent frequent genetic alterations in patients with acute myeloid leukemia (AML) associated with a favorable prognosis. Different types of NPM1 mutations have been described. The purpose of our study was to evaluate the relevance of different NPM1 mutation types with regard to clinical outcome. Our analyses were based on 349 NPM1-mutated AML patients treated in the AMLCG99 trial. Complete remission rates, overall survival and relapse-free survival were not significantly different between patients with NPM1 type A or rare type mutations. The NPM1 mutation type does not seem to play a role in risk stratification of cytogenetically normal AML.
authors.affiliation: Laboratory for Leukemia Diagnostics, Dept. of Internal Medicine III, University Hospital Munich Großhadern, Ludwig-Maximilian-University (LMU), Munich, Germany; Clinical Cooperative Group Pathogenesis of Acute Myeloid Leukemia, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany.
authors.forename: Friederike
authors.initials: F
authors.lastname: Pastore
authors.affiliation: Laboratory for Leukemia Diagnostics, Dept. of Internal Medicine III, University Hospital Munich Großhadern, Ludwig-Maximilian-University (LMU), Munich, Germany; Clinical Cooperative Group Pathogenesis of Acute Myeloid Leukemia, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany.
authors.forename: Philipp A
authors.initials: PA
authors.lastname: Greif
authors.affiliation: Laboratory for Leukemia Diagnostics, Dept. of Internal Medicine III, University Hospital Munich Großhadern, Ludwig-Maximilian-University (LMU), Munich, Germany.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Schneider
authors.affiliation: Laboratory for Leukemia Diagnostics, Dept. of Internal Medicine III, University Hospital Munich Großhadern, Ludwig-Maximilian-University (LMU), Munich, Germany.
authors.forename: Bianka
authors.initials: B
authors.lastname: Ksienzyk
authors.affiliation: Laboratory for Leukemia Diagnostics, Dept. of Internal Medicine III, University Hospital Munich Großhadern, Ludwig-Maximilian-University (LMU), Munich, Germany.
authors.forename: Gudrun
authors.initials: G
authors.lastname: Mellert
authors.affiliation: Laboratory for Leukemia Diagnostics, Dept. of Internal Medicine III, University Hospital Munich Großhadern, Ludwig-Maximilian-University (LMU), Munich, Germany.
authors.forename: Evelyn
authors.initials: E
authors.lastname: Zellmeier
authors.affiliation: Dept. of Oncology and Hematology, Krankenhaus Barmherzige Brüder, Regensburg, Germany.
authors.forename: Jan
authors.initials: J
authors.lastname: Braess
authors.affiliation: Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany.
authors.forename: Cristina M
authors.initials: CM
authors.lastname: Sauerland
authors.affiliation: Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany.
authors.forename: Achim
authors.initials: A
authors.lastname: Heinecke
authors.affiliation: Dept. of Internal Medicine A, Hematology and Oncology, University of Muenster, Muenster, Germany.
authors.forename: Utz
authors.initials: U
authors.lastname: Krug
authors.affiliation: Dept. of Internal Medicine A, Hematology and Oncology, University of Muenster, Muenster, Germany.
authors.forename: Wolfgang E
authors.initials: WE
authors.lastname: Berdel
authors.affiliation: Dept. of Internal Medicine A, Hematology and Oncology, University of Muenster, Muenster, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Buechner
authors.affiliation: German Society of Hematology and Oncology, Berlin, Germany.
authors.forename: Bernhard
authors.initials: B
authors.lastname: Woermann
authors.affiliation: Laboratory for Leukemia Diagnostics, Dept. of Internal Medicine III, University Hospital Munich Großhadern, Ludwig-Maximilian-University (LMU), Munich, Germany; Clinical Cooperative Group Pathogenesis of Acute Myeloid Leukemia, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Hiddemann
authors.affiliation: Laboratory for Leukemia Diagnostics, Dept. of Internal Medicine III, University Hospital Munich Großhadern, Ludwig-Maximilian-University (LMU), Munich, Germany; Clinical Cooperative Group Pathogenesis of Acute Myeloid Leukemia, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany.
authors.forename: Karsten
authors.initials: K
authors.lastname: Spiekermann
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D005260:Female; D015870:Gene Expression; D006801:Humans; D060828:Induction Chemotherapy / Q000379:methods; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000627:therapeutic use; D009154:Mutation; D009687:Nuclear Proteins / Q000235:genetics*; D000090243:Nucleophosmin; D011379:Prognosis; D012074:Remission Induction; D012307:Risk Factors; D016019:Survival Analysis; D013866:Thioguanine / Q000627:therapeutic use; D016896:Treatment Outcome; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; C000716967:NPM1 protein, human; D009687:Nuclear Proteins; D003561:Cytarabine; D000090243:Nucleophosmin; D008942:Mitoxantrone; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3; D013866:Thioguanine; D003630:Daunorubicin